Clinical trials
MDS clinical trials
Below are recruiting mds clinical trials, each written for real people, not researchers. We’re tracking 139 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06533761RecruitingPhase 1
Eganelisib alone or with chemo for relapsed AML
This trial tests an experimental drug called eganelisib, either alone or with the chemotherapy drug cytarabine, for people with relapsed or refractory acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It aims to see if the drug is safe and can help control the cancer.
Duarte, CaliforniaAges 18 years+ - NCT06536959RecruitingPhase 2
VA plus PD-1 inhibitor for relapsed AML and high-risk MDS
This trial tests a combination of two drugs—a chemotherapy-like agent called VA and a PD-1 inhibitor (which helps your immune system fight cancer)—for people with AML or high-risk MDS that has not responded to or returned after initial treatment. The goal is to see if this combination can work better than standard treatments alone.
Beijing, Beijing MunicipalityAges 18–70 - NCT06543381RecruitingPhase 1
Olutasidenib for IDH1-mutated blood cancers after transplant
This trial tests a drug called olutasidenib for people with certain blood cancers (AML, MDS, or CMML) that have a specific IDH1 gene change. The goal is to see if it can help prevent relapse after a donor stem cell transplant.
Duarte, CaliforniaAges 18 years+ - NCT06550713RecruitingPhase 1
Testing TQB3455 tablets for blood cancers with IDH2 mutation
This trial tests a new tablet, TQB3455, for people with certain blood cancers (MDS or AML) that have an IDH2 mutation. The goal is to see if the drug can help when other treatments haven't worked or aren't possible.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06569095Recruiting
Study of stem cells in myelodysplastic syndrome
This study looks at special stem cells in the blood or bone marrow of people with myelodysplastic syndromes (MDS). It aims to better predict how the disease might progress and help guide treatment decisions.
BeijingAges 15–70 - NCT06594445RecruitingPhase 1
GTB-3650 TriKE for high-risk MDS and relapsed AML
This trial tests a new immunotherapy called GTB-3650 TriKE for people with high-risk MDS or AML that has come back or not responded to treatment. It aims to boost your immune system to fight the cancer.
Minneapolis, MinnesotaAges 18 years+ - NCT07381751Recruiting
AI assessment of Parkinson's motor symptoms via video
This study uses artificial intelligence to analyze videos of standard motor tests (MDS-UPDRS Part III) for people with Parkinson's disease. It aims to see if AI can reliably assess your symptoms, which could lead to easier, more accessible monitoring in the future.
Hong KongAges 18–95 - NCT06612944RecruitingPhase 2
Preventing relapse after stem cell transplant for high-risk MDS
This trial tests whether giving medication after a donor stem cell transplant can prevent the return of very high-risk myelodysplastic syndrome (MDS). It is for people who have a suitable donor and are healthy enough for the procedure.
ShanghaiAges 18–70 - NCT06656494RecruitingPhase 1
New drug combo for myeloid blood cancers
This trial tests a new drug (ICP-248) combined with standard treatment azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). It aims to find out if the combo is safe and effective for those who haven't been helped by other treatments or cannot have strong chemotherapy.
New Haven, ConnecticutAges 18 years+ - NCT06764511Recruiting
Biosimilar EPO for anemia in low-risk MDS
This trial tests how well a biosimilar version of erythropoietin (a drug that boosts red blood cells) works in people with low-risk myelodysplastic syndrome (MDS) who have anemia. It aims to see if this treatment can safely improve low hemoglobin levels without needing more intensive therapies.
BolognaAges 18 years+ - NCT06765876RecruitingEarly Phase 1
CAR T-cell therapy for CD123+ blood cancers
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called CD123 on cancer cells. It is for people with certain blood cancers (AML, MDS-IB2, BPDCN, or ALL) that have come back or not responded to other treatments.
PragueAges 18–70 - NCT06802315RecruitingPhase 2
Radiation therapy before stem cell transplant for high-risk blood cancers
This trial tests a precise type of radiation called intensity modulated total marrow irradiation before a stem cell transplant. It aims to destroy cancer cells while reducing side effects for patients with high-risk leukemia or myelodysplastic syndrome.
Chicago, IllinoisAges 18–65 - NCT06834282RecruitingPhase 1
A study of CER-1236 for certain blood cancers
This trial tests an experimental cell therapy called CER-1236 for people with acute myeloid leukemia, myelodysplastic syndrome, or myelofibrosis. It aims to see if it can help treat these cancers.
Sacramento, CaliforniaAges 18–85 - NCT06839456RecruitingPhase 1/Phase 2
Stem cell addback to prevent infections after transplant
This trial tests whether adding back certain immune cells after a stem cell transplant can help prevent serious viral or fungal infections. It's for children and young adults up to age 25 who need a transplant for a blood cancer or other curable disease.
Philadelphia, PennsylvaniaAges 1 month–25 years - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Birmingham, AlabamaAges 18–66 - NCT06886425Recruiting
Study of how azacytidine works in blood cancers
This study looks at how certain enzymes in your body affect the way a drug called azacytidine works against blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The goal is to better understand who might benefit most from this treatment.
MarseilleAges 18 years+ - NCT07183878Recruiting
Venetoclax with BUCY conditioning for high-risk AML or MDS transplant
This trial tests whether adding venetoclax (a pill that targets cancer cells) to the standard chemotherapy regimen before a stem cell transplant improves outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It is for patients aged 12–60 whose cancer has specific high-risk features and who have a matched donor.
Hangzhou, ZhejiangAges 12–60 - NCT07205523Recruiting
High-altitude blood study for stem cell transplant patients
This study observes how blood and stem cell transplants work for patients with blood diseases at high altitude. It aims to learn more to help future patients.
Xining, QinghaiAges Any age - NCT07238712RecruitingPhase 2
New drug combo for high-risk blood cancer transplant
This trial tests a new combination of two chemotherapy drugs (bendamustine and cyclophosphamide) given before a stem cell transplant to help prevent graft-versus-host disease. It is for people with high-risk blood cancers who don't have a fully matched donor and will receive a partially matched transplant.
Saint PetersburgAges 18–70 - NCT07238686RecruitingPhase 2
Venetoclax plus microtransplant for higher-risk MDS
This study tests a combination of venetoclax (a targeted drug) with a mini stem cell transplant (called a microtransplant) using a partially matched donor. It is for people with higher-risk MDS who cannot have a standard transplant.
BeijingAges 18 years+ - NCT07680868Recruiting
Caris Chromoseq data collection for blood cancers
This study collects data from a special genetic test called Caris Chromoseq for people with certain blood cancers. It aims to learn more about these diseases and possibly guide better treatments.
Phoenix, ArizonaAges 18 years+ - NCT07270978RecruitingPhase 1
CD33-targeting cells for leukemia with leftover cancer cells
This trial tests a new treatment using special immune cells that target a protein called CD33 on leukemia cells. It's for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who still have small amounts of cancer cells left after other treatments.
Charlottesville, VirginiaAges 18 years+ - NCT07297576Recruiting
Sulforaphane to speed blood recovery after cord blood transplant
This trial tests if a natural compound called sulforaphane can help your blood cells recover faster after a cord blood transplant for high-risk blood cancers. If you qualify, you would receive this supplement along with your transplant.
TianjingAges 18 years+ - NCT07321626RecruitingPhase 1
Romiplostim for platelet recovery after stem cell transplant
This trial tests if romiplostim, a drug that helps the body make platelets, can speed up platelet recovery after a special type of stem cell transplant from a half-matched donor. It may help reduce bleeding risk during the recovery period.
HangzhouAges 18 years+
Hear when a new MDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mds?
- Yes. Clin2 currently lists 139 recruiting mds studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mds trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mds trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.